Sorrento goes to China with Covid drug; Vistagen touts early efficacy data on PMDD nasal spray
Sorrento Therapeutics’ oral Mpro inhibitor olgotrelvir has hit the primary endpoint and a key secondary endpoint in a Phase III trial that recruited adults with mild-to-moderate Covid. Subsequently, the company has reached out to China’s NMPA with an eye to submitting an NDA for expedited review.
In the primary endpoint of median time to sustained recovery of 11 Covid symptoms, olgotrelvir reached 8.6 days compared with 11 days with placebo (p=0.0001). Olgotrelvir also reduced participants’ viral RNA copy load compared with placebo at four days (p< 0.0001). — Ayisha Sharma
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
